EN DE
Watch Harrow Health Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Harrow Health Inc (HROW) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Harrow Health Inc stock $28.60, price $26.89, upside +6.4%, quality 47 out of 100. Rating: fairly valued. Calculated from audited financials with 13 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

HH Harrow Health Inc logo Some data Nov 6, 2026

Harrow Health Inc

HROW · US
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Generates free cash flow
Fair value $28.60 · Fairly valued (+6.4%)
Quality 47/100
Mixed Growth (revenue 5y +41.0 %/yr in USD)
Neutral coverage
Insiders bought $468,720 (6M) · sold $450,000
Some data
Loss-making · -13.5% net margin (TTM)
High debt
Trails peers (2/11)
Narrow moat 15/100
Watch Harrow Health Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$57.48 $5.75 Fair Value $28.60 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range $5.75 – $57.48 · fair‑value band $15.10 – $55.01 · the $26.89 price screens below the $28.60 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.

Follow Harrow Health in your weekly email

Every Wednesday you see whether Harrow Health is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments.

Show moreShow less

The company offers ImprimisRx, an ophthalmology-focused compounded medications.

It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis.

In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop.

The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.

Stock analysis

Harrow Health Inc (HROW) currently trades at $26.89, while our model-based Fair Value estimate is $28.60, so the stock looks roughly fairly valued today (gap 6.0%).

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of $32.18 per share, and 5 of the 13 models we run sit above the $26.89 price.

Bear case: the Earnings-Based group reads lowest at $4.89, and 8 of the 13 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $15.10 (bear) to $55.01 (bull), the price of $26.89 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Harrow Health Inc reported revenue of $272M in FY2025 versus $72.5M in FY2021, a compound +39.2%/yr. Reported net income was −$5.1M in FY2025.

Key figures

Market cap $993M Small · P/E ex one-offs 134.1 · P/S ratio 3.94 · EPS (TTM) $−0.9900 · Net margin −13.5% · Return on equity −116% · Return on assets (EBIT) 3.0% (5-year average) · Operating margin −15.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 15 out of 100 (medium confidence).

What moves the price

The share trades about 51% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 6%, HROW screens cheaper than that median.

Fair Value models

Bear $15.10 Fair Value $28.60 Bull $55.01
Price $26.89 · Upside +6.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV $3.64 $4.89 $5.96 74
FCF DCF $21.88 $35.61 $77.94 72
Growth DCF $20.25 $41.52 $75.50 72
All 13 models by family
DCF Models
FCF DCF $21.88 $35.61 $77.94 72
Owner Earnings $8.99 $24.97 $56.60 67
5Y Revenue Exit $10.52 $19.36 $37.66 66
5Y EBITDA Exit $15.10 $28.60 $55.01 69
10Y Revenue Exit $13.84 $30.67 $39.81 64
10Y EBITDA Exit $17.44 $40.14 $78.38 62
Earnings-Based
EPV $3.64 $4.89 $5.96 74
Multiples
EV/EBIT $8.36 $12.73 $17.11 65
EV/EBITDA $11.55 $16.99 $22.43 66
EV/Revenue $4.60 $8.61 $12.63 52
Growth DCF
Growth DCF $20.25 $41.52 $75.50 72
Rev-Margin DCF $11.96 $22.83 $45.73 66
Economic Profit
ROIC Compounder $5.86 $10.19 $13.47 68

Open the full fair value analysis →

Quality Score breakdown

Overall quality 47/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 32
How much profit the company makes from its sales and capital
Quality Growth 84
Are margins and returns getting better?
Cashflow 76
Do the profits arrive as real cash?
Financial strength 32
Debt, balance sheet and risk of trouble
Investment 33
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 9
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 5
Distance to the 52-week high, does not count
New shares 50
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 4 officers or directors bought shares worth $468,720, most recently on May 18, 2026. Over the same period, one person sold shares worth $450,000. Buying cluster

  • SaleAmir ShojaeiCHIEF SCIENTIFIC OFFICER11,250 shares at $40.00$450,000Aug 14, 2026
  • BuyLauren P SilvernailDirector1,000 shares at $31.00$31,000May 18, 2026
  • BuyAdrienne L GravesDirector1,000 shares at $31.07$31,070May 18, 2026
  • BuyAndrew R. BollPRESIDENT AND CFO3,500 shares at $29.90$104,650May 14, 2026
  • BuyMark L BaumCHIEF EXECUTIVE OFFICER, Director10,000 shares at $30.20$302,000May 14, 2026
  • SaleOpaleye Management Inc.10% owner3× since Jan 6, 2026: 223,572 shares, avg. $41.08$9.2MMar 4, 2026

Plus one other filing such as a grant, option exercise or tax withholding. It is not a market purchase or sale.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 59/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+36.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+45.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+41.0%
Start year 2020 (pandemic). Over 10 years: +39.6% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+83.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
0.8% (2020) → 14.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+15.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+40.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +13.1% a year for the price and +37.1% for the forecasts.
Forecast 2026 (sales)+28.6%
Forecast 2027 (sales)+53.2%
Projected 2028 (sales)+46.8%
Projected 2029 (sales)+40.4%
Projected 2030 (sales)+34.0%

Watch HROW, get fair value alerts →

Earlier news

News mood ⓘNews mood, the average tone of recent news (91 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.

Compare Harrow Health Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks

Beats the industry median on 2/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 47 · Below median
Fair Value upside +6.4% · Above median
Profitability
Return on assets −1.3% · Bottom 25%
Net margin (12 months) −13.5% · Bottom 25%
Operating margin (12 months) −15.6% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 10.9% · Above median
Balance sheet
Debt / equity 4.64× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 18.93× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 3.60× · Pricier than median
Price / free cash flow (fiscal year) 23.2× · Pricier than median
EV/EBITDA 65.7× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)42 · sector 15
FUTURE (revenue growth)55 · sector 25
PAST (return on equity)0 · sector 29
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $111.63 +41% vs HROW
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.43 ¥55.21 +9% vs HROW
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,860 ₹1,947 +5% vs HROW
Haleon plc HLN $9.14 $8.61 −6% vs HROW
Merck KGaA MRK €148.75 €109.18 −27% vs HROW
Galderma Group GALD CHF 191.75 CHF 109.86 −43% vs HROW
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs HROW
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs HROW
Sandoz Group SDZ CHF 83.78 CHF 39.70 −53% vs HROW
Divi's Laboratories Limited DIVISLAB ₹10,321 ₹1,567 −85% vs HROW

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Harrow Health Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Harrow Health Inc Fair Value". https://www.fairvalue-calculator.com/stock/HROW

Frequently asked questions

Is Harrow Health Inc (HROW) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $28.60 versus a price of $26.89, about +6% upside (fairly valued).
What is the fair value of HROW?
Our model-based fair value for Harrow Health Inc is $28.60 (as of Nov 6, 2026), built from audited fundamentals. The current price: $26.89.
What is the quality score of HROW?
Harrow Health Inc has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Harrow Health Inc (HROW)?
Our model-based price target is the fair value of $28.60 (as of Nov 6, 2026) from 13 valuation models. Cautious scenario $15.10, optimistic scenario $55.01. It is a calculation from audited fundamentals, not an analyst target.
What is the Harrow Health Inc stock forecast for 2026?
Our models put fair value at $28.60, about +6% upside versus a price of $26.89 (fairly valued). Cautious scenario $15.10, optimistic scenario $55.01. The calculation is refreshed regularly with new filings.
What is the revenue of Harrow Health Inc (HROW)?
Harrow Health Inc reported trailing-twelve-month revenue of about $276M (latest available figure, as of Nov 6, 2026).
What growth is priced into Harrow Health Inc (HROW)?
For today's price to be fair in a discounted-cash-flow model, Harrow Health Inc would have to grow free cash flow by +15.8 % per year for five years (discount rate 9.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +41.0 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of HROW use?
Our models discount Harrow Health Inc at 9.8 %: a base by market capitalisation (small), damped by beta 0.19, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Harrow Health Inc that is +15.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.8 %) and the same formula as our fair value.
How much growth has Harrow Health Inc (HROW) delivered so far?
Over the past 5 years revenue at Harrow Health Inc grew +41.0 % a year. The price currently implies free-cash-flow growth of +15.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Harrow Health Inc (HROW) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Harrow Health Inc (+15.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Harrow Health Inc (HROW)?
The free-cash-flow yield on the price is 4.26 %: that much free cash flow Harrow Health Inc produces per unit of market value. When it exceeds the discount rate of our models (9.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Harrow Health Inc (HROW)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Harrow Health Inc it is $28.60 per share (as of Nov 6, 2026), against a price of $26.89. It is the blended result of 13 valuation models in 5 families (DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit).
Is Harrow Health Inc stock overvalued or undervalued in 2026?
As of Nov 6, 2026, HROW trades below its calculated fair value: price $26.89, fair value $28.60, a gap of about +6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HROW?
No. The price is what the market pays today ($26.89); the fair value is what the company's own numbers justify ($28.60). For Harrow Health Inc the two are $1.71 per share apart. That gap is exactly why we show both numbers side by side.
How much is Harrow Health Inc worth?
The market values Harrow Health Inc at about $993M (market capitalisation, as of Nov 6, 2026). Per share that is $26.89; our models calculate a fair value of $28.60 per share.
What do the bullish and bearish scenarios say about HROW?
Our models span a range for Harrow Health Inc: cautious scenario $15.10, base $28.60, optimistic $55.01 per share (as of Nov 6, 2026, price $26.89). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Harrow Health Inc (HROW)?
Balance-sheet figures for Harrow Health Inc (as of Nov 6, 2026): return on equity −116.1%, debt of 4.64 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is HROW from its 52-week high?
Harrow Health Inc trades at $26.89, about 51% below its 52-week high of $54.80 and 3% above the low of $26.04 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $28.60 is for.
Which stocks are comparable to Harrow Health Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Harrow Health Inc stock attractive at the current price?
The data as of Nov 6, 2026: price $26.89, calculated fair value $28.60 (+6%), Quality Score 47/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HROW calculated?
We run Harrow Health Inc through 13 models from 5 families: DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of $28.60 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Harrow Health Inc currently trades 6% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Harrow Health Inc (HROW)?
The closing price on Nov 6, 2026 was $26.89. Our model-based fair value is $28.60, about +6% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Harrow Health Inc right now?
The model range is unusually wide ($15.10 to $55.01). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits close to our fair value, market and models broadly agree here, little valuation tension.

Key figures of Harrow Health Inc

How large is the market capitalisation of Harrow Health Inc (HROW)?
The market capitalisation of Harrow Health Inc is $993M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Harrow Health Inc (HROW) excluding one-off items?
Excluding one-off items, the price-to-earnings ratio of Harrow Health Inc is 134.1 (fiscal year 2025, the reported result was a loss).
What is the P/S ratio of Harrow Health Inc (HROW)?
The price-to-sales ratio of Harrow Health Inc is 3.94 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Harrow Health Inc (HROW)?
Earnings per share at Harrow Health Inc are $−0.9900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Harrow Health Inc (HROW)?
The net margin of Harrow Health Inc is −13.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Harrow Health Inc (HROW)?
The return on equity (ROE) of Harrow Health Inc is −116% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Harrow Health Inc (HROW)?
On an EBIT basis the return on assets of Harrow Health Inc is 3.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Harrow Health Inc (HROW)?
The operating margin of Harrow Health Inc is −15.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Harrow Health Inc (HROW)?
Revenue at Harrow Health Inc is growing +10.9% versus a year earlier (3y avg +45.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Harrow Health Inc (HROW)?
Earnings per share at Harrow Health Inc are growing −10.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Harrow Health Inc (HROW) carry?
The net debt of Harrow Health Inc is $179M (fiscal year 2025, ≈ 4.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Harrow Health Inc in the live analysis

One click puts Harrow Health Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.